Aaron Weitzman
The pairing of private equity and venture capital firms focused on life sciences seems to provide a win-win, giving PE firms early access to drug discovery and giving VC firms capital and access to the PE firms' LPs.
Probitas Partners annual LP survey revealed that maintaining established relationships with fund managers soared this year, reflecting the surging fundraising environment and its impact on fund manager access.
The goal is to reach the 10% allocation by 2024, with the pension fund also ramping up its co-investments, as scaling co-investments is reducing program costs.
In the crowded markets, GPs have more options than ever to achieve exits for their portfolio companies.
More LPs consider ESG standards as one of many factors in potential commitments, but generally it's not risen to the level of being a deciding factor when backing a manager.
AmorChem, an early-stage life sciences fund managed by Canadian venture capital firm GeneChem, has entered into an agreement with Hôpital Maisonneuve-Rosemont and Univalor to participate in the financing of research at the Personalized Cancer ImmunoTherapy Program. The program, which is sponsored by Genome Canada, focuses on the development and clinical implementation of innovative personalized anti-cancer immunotherapies. The investment is AmorChem's second in the program. Earlier in 2015, the fund partnered with the University of Waterloo on a mucoadhesive nanotechnology project.
News briefs about European funds, including EIF, Northzone, Orbimed, Cube Infrastructure, ESA, Team Europe
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: